for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Akcea Therapeutics Inc

AKCA.OQ

Latest Trade

19.31USD

Change

0.20(+1.05%)

Volume

53,031

Today's Range

19.00

 - 

19.43

52 Week Range

13.90

 - 

35.82

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Akcea Reports Q3 Loss Per Share $0.34

Nov 5 (Reuters) - Akcea Therapeutics Inc <AKCA.O>::AKCEA REPORTS FINANCIAL RESULTS AND HIGHLIGHTS FOR THIRD QUARTER 2019.REPORTED Q3 2019 GLOBAL NET PRODUCT REVENUES OF $12 MILLION.QTRLY LOSS PER SHARE $0.34.AKCEA'S TOTAL REVENUE FOR THREE MONTHS ENDED SEPTEMBER 30, 2019 WAS $21 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.47, REVENUE VIEW $22.5 MILLION -- REFINITIV IBES DATA.

Akcea Announces Damien Mcdevitt As Interim Chief Executive Officer

Sept 23 (Reuters) - Akcea Therapeutics Inc <AKCA.O>::AKCEA ANNOUNCES CEO TRANSITION AND ELECTS TWO NEW BOARD MEMBERS.AKCEA THERAPEUTICS INC - APPOINTED DAMIEN MCDEVITT., A MEMBER OF ITS BOARD OF DIRECTORS, AS INTERIM CHIEF EXECUTIVE OFFICER, EFFECTIVE IMMEDIATELY.AKCEA THERAPEUTICS INC - IN ADDITION, MICHAEL J. YANG AND JOSEPH 'SKIP' KLEIN III HAVE JOINED CO'S BOARD OF DIRECTORS.AKCEA THERAPEUTICS - DEPARTURES OF PAULA SOTEROPOULOS, CEO, SARAH BOYCE, PRESIDENT, AND JEFF GOLDBERG, CHIEF OPERATING OFFICER, EFFECTIVE IMMEDIATELY.AKCEA THERAPEUTICS INC - SOTEROPOULOS AND BOYCE HAVE ALSO RESIGNED FROM CO'S BOARD OF DIRECTORS.AKCEA THERAPEUTICS INC - SOTEROPOULOS AND GOLDBERG WILL SERVE AS ADVISORS TO CO TO ENSURE SMOOTH TRANSITION.

Akcea Reports Q2 2019 Results

Aug 6 (Reuters) - Akcea Therapeutics Inc <AKCA.O>::AKCEA REPORTS FINANCIAL RESULTS AND HIGHLIGHTS FOR SECOND QUARTER 2019.AKCEA THERAPEUTICS INC - QTRLY TOTAL REVENUE $27 MILLION.AKCEA THERAPEUTICS INC - AS OF JUNE 30, 2019, CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $296 MILLION COMPARED TO $253 MILLION AT DECEMBER 31, 2018.

Akcea Therapeutics Reports Q1 Earnings Per Share $0.34

May 8 (Reuters) - Akcea Therapeutics Inc <AKCA.O>::AKCEA REPORTS FINANCIAL RESULTS AND HIGHLIGHTS FOR FIRST QUARTER 2019.Q1 REVENUE $164 MILLION VERSUS REFINITIV IBES ESTIMATE OF $168.6 MILLION.Q1 EARNINGS PER SHARE $0.34.Q1 EARNINGS PER SHARE ESTIMATE $0.98 -- REFINITIV IBES DATA.RECEIVED MARKETING AUTHORIZATION FOR WAYLIVRA(®) (VOLANESORSEN) IN E.U..AS OF MARCH 31, 2019, AKCEA HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $322 MILLION.

Akcea And Ionis Announce Approval Of Waylivra In The European Union

May 7 (Reuters) - Akcea Therapeutics Inc <AKCA.O>::AKCEA AND IONIS ANNOUNCE APPROVAL OF WAYLIVRA® (VOLANESORSEN) IN THE EUROPEAN UNION.AKCEA THERAPEUTICS - APPROVAL OF WAYLIVRA IN EU AS ADJUNCT TO DIET IN ADULT PATIENTS WITH GENETICALLY CONFIRMED FCS AND AT HIGH RISK FOR PANCREATITIS.

Akcea Reports Financial Results For Fourth Quarter

Feb 26 (Reuters) - Akcea Therapeutics Inc <AKCA.O>::AKCEA REPORTS FINANCIAL RESULTS AND HIGHLIGHTS FOR FOURTH QUARTER AND YEAR END 2018.Q4 LOSS PER SHARE $0.79.Q4 EARNINGS PER SHARE ESTIMATE $-0.73 -- REFINITIV IBES DATA.TOTAL REVENUE FOR Q4 $10 MILLION.

Akcea Q3 Loss Per Share $0.73

Nov 5 (Reuters) - Akcea Therapeutics Inc <AKCA.O>::AKCEA REPORTS FINANCIAL RESULTS AND HIGHLIGHTS FOR THIRD QUARTER 2018.QTRLY TOTAL REVENUE $19.2 MILLION VERSUS $9.9 MILLION.QTRLY LOSS PER SHARE $0.73.Q3 EARNINGS PER SHARE VIEW $-0.80 -- THOMSON REUTERS I/B/E/S.Q3 REVENUE VIEW $16.8 MILLION -- THOMSON REUTERS I/B/E/S.

Akcea And Ionis Receive FDA Approval Of Tegsedi (Inotersen) For The Treatment Of The Polyneuropathy Of Hereditary Transthyretin-Mediated Amyloidosis In Adults

Oct 5 (Reuters) - Akcea Therapeutics Inc <AKCA.O>::AKCEA AND IONIS RECEIVE FDA APPROVAL OF TEGSEDI (INOTERSEN) FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS.AKCEA THERAPEUTICS INC - TEGSEDI IS NOW APPROVED IN U.S., EUROPEAN UNION AND CANADA.

Akcea Therapeutics Inc Files For Potential Mixed Shelf Offering Size Not Disclosed - SEC Filing

Sept 18 (Reuters) - Akcea Therapeutics Inc <AKCA.O>::AKCEA THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.

Akcea Therapeutics To Reduce Its Workforce By About 10 Pct

Sept 6 (Reuters) - Akcea Therapeutics Inc <AKCA.O>::AKCEA THERAPEUTICS INC - INTENDS TO REDUCE ITS WORKFORCE BY APPROXIMATELY 10%.AKCEA THERAPEUTICS - UNDER REORGANIZATION PLAN, EXPECTS TO INCUR Q3 RESTRUCTURING CHARGES IN THE RANGE OF $2.0 MILLION TO $2.5 MILLION.AKCEA THERAPEUTICS INC - ENACTED A PLAN TO REORGANIZE ITS WORKFORCE FOLLOWING FDA ISSUANCE OF CRL FOR ITS NEW DRUG APPLICATION FOR WAYLIVRA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up